Member Info for Traa-dy-Liooar

The grants are welcome news - they were signposted in the the need for the recent placement on 26.5

Rationale for the Placing

The Placing will provide the Company with the finance needed to help secure significant grant funding, subject to final approval, and enable the Company to progress its Phase 2 open-label clinical trial, with the first patients expected to be dosed in June 2026. The net proceeds will also allow the continued development of docetaxel-ChemoSeed for treatment of prostate cancer, which has demonstrated significant positive preclinical efficacy and safety results.

I would hope it is all systems go now to commence the programme.

When news flow then commences and SP rises it will give a better indication of who took the placing. Like the science although timelines have slipped.

Two cracking RNS in successive days. Sp starting to clear it's head after what was a very smelly placing. It will should now start to have traction.

Depends on how many comment letters (clarifications on the filing) the sec has, I think they have to be replied to in 2 weeks - longer if very technical. But the main thing is the process has commenced.

Nice to see this filed. The clock has started.

Have a small exposure here. Like the concept, but it is clear there is a placing looming large. The Co have missed some predicted news events. There are, and have beeen, some big , regular sellers. It is all rather flat.

Excellent volume for a no news day, but as we know there is a whole load of news to come in relatively short order.

MKA will move on newsflow. The placing was very poor, but we move on and I sense some major news items on the near horizon.

Looking perkier here. Looking forward to newsflow.

V interesting article. Time will tell but looks promising

If you were not in MKA then tomorrow will be an absolute gift to get in at a ridiculous price what with what is on the horizon. Unless some are really hacked off I would be surprised if it dropped much below the placing but who knows. I have taken some in the retail offer as a few p either way is notsomething I hoped to dwell on by the year end.

Disappointing. never nice being on the outside when these events happen. Awful price but will take some in the retail offer, as there is a wealth of news flow to come. Company needs to up its game with comms.

Today- cleared a lot. Seems clear peeps want in at this price given the recent news and potential returns

Nice news. , pity London South East can't get the RNS out on their sites.

This will go a lot lower.

Decent buying today after yesterdays sell off taking it back down to 10's. in the news month now.

Well they are well funded now and the SP is very strong despite some selling it to rise apace. No idea where this ends up but nice to be along for the ride.

Should get some news in the next few weeks. Here's a reminder of the trial, taken from the RNS. The open label is most interesting. First patient dosing will undoubtedly bring attention to the share. Fully expect it to rise accordingly.

The approved study, titled "An Open-label Phase 2 Safety and Efficacy Trial of Irinotecan ChemoSeed Administered Directly into the Resection Margin in Patients with Surgically Resectable Glioblastoma", is designed to assess the safety, tolerability, and efficacy of irinotecan-ChemoSeed, CRISM's proprietary, biodegradable implant technology delivering sustained-release irinotecan directly into the tumour resection margin following surgical removal of the glioblastoma tumour. The trial has been designed in alignment with regulatory expectations for future marketing authorisation submissions.

Key Highlights:

· Regulatory (MHRA) and Ethical (REC) approval received

· Trial confirmed to initiate in Q1 2026 at leading UK neuro-oncology centres

· Open-label format supports interim analysis, reporting of early results and potential for expedited regulatory approval

· ChemoSeed platform targets local recurrence with sustained, localised chemotherapy

· Registration-grade Phase 2 design supports pathway to marketing authorisation and commercialisation.

Professor Chris McConville, Chief Scientific Officer of CRISM Therapeutics, commented:"We are delighted to have received both regulatory and ethical approval to begin our Phase 2 study. This is a critical inflection point for CRISM as we prepare to clinically validate our ChemoSeed platform in patients with glioblastoma, an area of immense unmet need. With these approvals secured, we are now in a position to move rapidly into trial activation and first patient dosing. We believe the data from this study could serve as a foundation for future regulatory submissions and commercial advancement."

Professor Garth Cruickshank, Emeritus Professor of Neurosurgery at the University of Birmingham, and scientific advisor to CRISM, added: "This is a very exciting development in the drive to treat one of the most complex cancers. The technical innovation of putting the tumour killing drug irinotecan into the tumour site at the time of the surgery offers the very best chance to hit the tumour when it is at its smallest. The release process at least covers the time until radiotherapy and or temozolomide are introduced providing a much more powerful sustained antitumour assault. The local deposition of drug already known to attack glioblastoma, avoids systemic side effects, so no additional problems for patients. This approach safely enables high antitumour concentrations without evidence of associated neurotoxicity. Furthermore, the spectrum of patients likely to respond is greater than for any gene targeted or existing immunotherapy. Patients and surgeons will surely welcome such a pragmatic and truly practical step forward in treatment for glioblastoma."

Nice increase today and news still to land.

Also almost half the shares are locked in until Dec 2026. so limited available f/f

Spread over three years like Uni of Toronto, so with conversion rates about£1.4m for the first year for both. Of cours they will have admin etc . raised £2.5 so still some headroom there. But you have to speculate to accumulate. any raise would be at a much higher Sp.